756
Case-control study on risk factors for prescription opioid abuse among patients with pain
Corey M. Bieber, MPH1, Heather N. Thomson, MS(c)2, David Borsook, MD, PhD3, Michael J. Brennan, MD4, Stephen F. Butler, PhD1, Katherine Fernandez, MPH1, Robert Jamison, PhD5, Eric Osgood, BS6, Jennifer Sharpe Potter, PhD, MPH7, Rodger Weiss, MD7, and Nathaniel P. Katz, MD, MS1. (1) Inflexxion Inc., 320 Needham St. Suite 100, Newton, MA 02464-1594, (2) Endo Pharmaceuticals, 15 Pine Ledge Way, Norfolk, CT 06058, (3) Brain Imaging Center, McLean Hospital, 115 Mill Street, Belmont, MA 02478-9106, (4) The Pain Center of Fairfield, 1300 Post Road, Suite 203, Fairfield, CT 06430, (5) Pain Management Center, Brigham and Women's Hospital, 850 Boylston Street, Chestnut Hill, MA 02467, (6) School of Medicine, Tufts University, 145 Harrison Avenue, Boston, MA 02111, (7) Alcohol & Drug Abuse Treatment Program, McLean Hospital, Proctor House, 115 Mill Street, Belmont, MA 02478
While opioid analgesics have been shown to be effective in the treatment of chronic pain, they are also associated with risk of addiction. Little is known about what significance a patient's initial experience with opioid medications may have in predicting future development of addiction. This case-control study proposes to generate hypotheses to identify risk factors at the time of initial exposure to opioids for pain. Cases were individuals in an inpatient substance abuse treatment center for primary prescription opioid abuse. Controls, individuals who were using prescribed opioids for at least 3 months who had not developed addiction, were from a pain management center. Subjects completed a number of measures to capture data from the individual's first exposure to prescription opioids. Between-group differences on the instruments as well as on the individual items were compared using t-tests for continuous variables and Fisher's exact test for categorical variables. The ARCI, designed to measure euphoria and other drug effects, showed the most significant between-group difference. Those items significant for morphine showed a difference between means of 5.68 (95% CI 3.58,7.78) with a t-value of 5.31 (p-value <.0001) Item analysis of the ARCI showed significant differences (cases 81%, controls 0) between groups: “A thrill had gone through me” and “I feared I would lose the contentment that I had then.” Euphoria and other differences in the subjective response to opioids suggest the hypotheses that (1) a subgroup of patients with pain does develop euphoria when taking opioids for pain, and (2) this experience of euphoria may be a risk factor for the eventual development of prescription opioid addiction.
